Monoprost (Latanoprost)

Latanoprost, the active ingredient in Monoprost, is a prostaglandin analog presented as an ophthalmic solution for ocular use. It is employed to lower intraocular pressure in patients with open-angle glaucoma or ocular hypertension. GNH USA supplies Monoprost as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Monoprost is a prostaglandin analog indicated for conditions that require reduction of intraocular pressure. Open-angle glaucoma: lowers intraocular pressure to help preserve visual field and prevent optic nerve damage. Ocular hypertension: reduces elevated eye pressure to decrease the risk of developing glaucoma.

Latanoprost may cause ocular and systemic reactions, most of which are mild and transient.

Common Side Effects: - Eye irritation or burning sensation after instillation. - Conjunctival hyperemia (eye redness). - Increased eyelash growth and length. - Darkening of the iris color over time. - Transient blurred vision.

Serious or Rare Side Effects: - Uveitis or severe intraocular inflammation. - Allergic reactions such as swelling of the eyelid or face. - Persistent ocular pain or visual disturbances. - Corneal edema or keratitis. - Rare cases of macular edema.

Patients should be counseled on proper use and monitored for ocular changes. Monitor intraocular pressure: ensure therapeutic target is achieved. Assess for ocular infections: avoid use if active infection is present. Avoid use in patients with active ocular inflammation: may exacerbate condition. Inform patients about possible iris color change: irreversible darkening may occur. Store at room temperature: keep bottle tightly closed, protect from light and freezing.

Latanoprost may interact with other ocular or systemic agents, requiring vigilance.

Major Interactions (Avoid): - Concomitant use with other prostaglandin analogs: may increase risk of ocular side effects. - Use with ocular anesthetics: can heighten corneal toxicity.

Moderate Interactions (Monitor Closely): - Combined therapy with carbonic anhydrase inhibitors: additive intraocular pressure reduction, monitor pressure. - Non‑steroidal anti‑inflammatory eye drops: may alter drug absorption. - Systemic beta‑blockers: potential for enhanced hypotensive effect, observe systemic blood pressure.